STAT5B (Ab-731) Antibody

What is STAT5B and why is it important in research?

STAT5B (Signal Transducer and Activator of Transcription 5B) is a transcription factor that plays dual critical roles in cellular function: signal transduction and transcriptional activation. It mediates cellular responses to various cytokines, particularly KITLG/SCF (KIT ligand/stem cell factor), and several growth factors that regulate vital biological processes . STAT5B binds to the GAS (gamma-activated sequence) element and can activate prolactin-induced transcription, making it crucial for several developmental and homeostatic pathways . The protein is highly conserved across species including humans, mice, and rats, allowing for translational research across these experimental models . STAT5B's importance in research stems from its involvement in numerous physiological processes, including immune cell development, hematopoiesis, and growth regulation, as well as its dysregulation being implicated in various cancers and immunological disorders . Understanding STAT5B function has significant implications for therapeutic applications, particularly in cancers where growth factor receptor overexpression is common, such as advanced breast cancer .

What distinguishes STAT5B (Ab-731) Antibody from other STAT5B antibodies?

The STAT5B (Ab-731) Antibody is specifically designed to recognize the region surrounding the serine 731 phosphorylation site (A-P-S-P-A sequence) of human STAT5B protein, making it distinct from antibodies targeting other epitopes . This specificity allows researchers to detect total STAT5B protein rather than just phosphorylated forms, providing a comprehensive view of STAT5B expression levels regardless of activation state . The antibody is generated as a rabbit polyclonal, which offers advantages in terms of recognizing multiple epitopes around the target region, potentially enhancing sensitivity in applications like Western blotting and immunohistochemistry . Unlike antibodies targeting the more commonly studied tyrosine 699 phosphorylation site (critical for canonical activation), this antibody allows researchers to examine regulatory mechanisms involving serine phosphorylation, which may have distinct functional consequences . Additionally, the antibody has been validated for cross-reactivity with mouse and rat STAT5B, enabling consistent reagent use across multiple experimental models .

What are the known phosphorylation sites in STAT5B and their functional significance?

STAT5B undergoes phosphorylation at multiple sites that regulate its function differently. The tyrosine 699 (Tyr-699) residue is the canonical phosphorylation site essential for STAT5B dimerization, nuclear translocation, and DNA binding; mutation at this site severely impairs transcriptional activity, highlighting its critical importance . Notably, research has identified several novel tyrosine phosphorylation sites induced by epidermal growth factor (EGF) but not by growth hormone (GH): Tyr-725, Tyr-740, and Tyr-743 . These sites appear to be involved in negative regulation of transcription, as demonstrated through site-directed mutagenesis and luciferase assays using STAT5-specific DNA sequences . Beyond tyrosine phosphorylation, STAT5B also undergoes serine phosphorylation, including at Ser-731 (the region recognized by the STAT5B Ab-731 antibody), which may affect protein stability, DNA binding affinity, or interactions with other transcriptional cofactors . Understanding these distinct phosphorylation patterns is crucial because they represent differential regulation mechanisms depending on the activating stimulus (cytokine versus growth factor), potentially explaining the diverse biological responses mediated by STAT5B .

What are the validated applications for STAT5B (Ab-731) Antibody?

The STAT5B (Ab-731) Antibody has been validated for several key research applications that facilitate the investigation of STAT5B expression and function. Western blotting (WB) is a primary application where the antibody demonstrates strong performance for detecting endogenous levels of total STAT5B protein, as validated in RAW264.7 cell extracts treated with EGF (200ng/ml for 30 minutes) . Immunohistochemistry (IHC) represents another validated application, allowing researchers to examine STAT5B localization and expression patterns in tissue sections with detailed morphological context . The antibody is also suitable for enzyme-linked immunosorbent assay (ELISA), providing a quantitative method for measuring STAT5B protein levels in various sample types . For optimal results across these applications, the antibody is typically used at a working concentration derived from its stock concentration of 1 mg/ml, properly diluted in the appropriate buffer systems . Researchers should note that while these applications have been validated, optimization may be required for specific experimental systems, particularly when working with different cell lines or tissue types .

How should samples be prepared for optimal STAT5B detection using the Ab-731 antibody?

For optimal detection of STAT5B using the Ab-731 antibody, sample preparation should be tailored to the specific application while preserving the antibody's target epitope. For Western blotting applications, cells should be lysed in a buffer that preserves protein integrity while efficiently extracting nuclear proteins where activated STAT5B may reside; a buffer containing phosphate buffered saline with protease and phosphatase inhibitors is recommended to prevent degradation and dephosphorylation . Treatment of cells with appropriate stimuli before lysis can enhance detection of STAT5B; for example, stimulation with EGF (200ng/ml for 30 minutes) has been validated to effectively activate STAT5B signaling pathways in RAW264.7 cells . For immunohistochemistry, tissues should be fixed with paraformaldehyde or formalin and embedded in paraffin, followed by antigen retrieval methods (typically heat-induced epitope retrieval in citrate buffer pH 6.0) to expose the epitope that might be masked during fixation . For all applications, inclusion of appropriate positive controls (such as RAW264.7 cells treated with EGF) and negative controls (such as secondary antibody-only or isotype controls) is essential for validating specificity . Sample storage conditions are equally important, with protein lysates being stable at -80°C and tissue sections best prepared fresh or stored according to standard archival procedures .

What are the recommended protocols for Western blotting with STAT5B (Ab-731) Antibody?

For Western blotting with STAT5B (Ab-731) Antibody, a carefully optimized protocol is essential to achieve specific and sensitive detection. Begin with sample preparation by lysing cells in a buffer containing protease and phosphatase inhibitors, followed by determination of protein concentration using a compatible assay such as BCA or Bradford . Load 20-50 μg of total protein per lane on an 8-10% SDS-PAGE gel (STAT5B is approximately 90 kDa), and separate proteins using standard electrophoresis conditions . Transfer proteins to a PVDF or nitrocellulose membrane using wet or semi-dry transfer systems, and block the membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature . Incubate the membrane with STAT5B (Ab-731) antibody diluted appropriately (typically 1:500 to 1:2000) in blocking buffer overnight at 4°C, followed by washing three times with TBST . Apply a compatible HRP-conjugated secondary antibody (such as goat anti-rabbit IgG) at a 1:5000 to 1:10000 dilution for 1-2 hours at room temperature, wash thoroughly, and develop using ECL substrate with appropriate exposure settings . Validation data demonstrates successful detection of STAT5B in RAW264.7 cells treated with EGF (200ng/ml for 30 minutes), which can serve as a positive control for experimental optimization .

How can STAT5B activation be experimentally induced for positive control samples?

Creating reliable positive control samples through experimental induction of STAT5B activation is critical for validating antibody performance and experimental systems. Epidermal growth factor (EGF) treatment has been well-validated for STAT5B activation, with optimal conditions being 200ng/ml for 30 minutes in RAW264.7 cells as demonstrated in the antibody validation data . Growth hormone (GH) represents another potent activator of STAT5B through canonical JAK-STAT signaling, though the activation mechanism differs from that of EGF, with GH requiring the canonical Tyr-699 phosphorylation while EGF can activate STAT5B through alternative tyrosine residues (Tyr-725, Tyr-740, and Tyr-743) . For cell lines that may not express sufficient levels of EGF receptor (EGFR) naturally, it's important to note that EGFR overexpression may be necessary for robust EGF-induced STAT5B activation, as demonstrated in HEK293 cells stably overexpressing EGFR and in the MDA-MB468 breast cancer cell line which naturally overexpresses EGFR . Cytokine stimulation, particularly with interleukins (IL-2, IL-7, IL-15) that signal through receptors sharing the common gamma chain, offers an alternative approach for STAT5B activation in immune cells . Regardless of the activation method chosen, time-course and dose-response experiments should be conducted to determine optimal conditions for each specific cell type and experimental question .

What is known about the relationship between EGF-induced versus cytokine-induced STAT5B activation?

Research utilizing tools like the STAT5B (Ab-731) Antibody has revealed fundamental differences between EGF-induced and cytokine-induced STAT5B activation, with important implications for downstream signaling. Unlike cytokine activation (such as by growth hormone), EGF-induced STAT5B activation requires overexpression of the EGF receptor (EGFR), as demonstrated in HEK293 cells with stable EGFR overexpression and in MDA-MB468 breast cancer cells that naturally overexpress EGFR . A striking mechanistic distinction is that while growth hormone-induced activation absolutely requires tyrosine phosphorylation at the canonical Tyr-699 site, EGF can still induce tyrosine phosphorylation of STAT5B Y699F mutants, indicating alternative activation mechanisms . Metabolic labeling studies and site-directed mutagenesis have identified three novel EGF-induced tyrosine phosphorylation sites: Tyr-725, Tyr-740, and Tyr-743, which may be involved in negative regulation of transcription as determined through luciferase assays using STAT5-specific DNA sequences . These differential phosphorylation patterns likely contribute to the distinct transcriptional programs induced by growth factors versus cytokines, potentially explaining the different biological outcomes observed . This relationship between EGF and STAT5B activation has particular relevance for cancer research, as EGFR overexpression is common in many cancers, including advanced breast cancer, suggesting potential therapeutic applications targeting this specific activation pathway .

How can STAT5B (Ab-731) Antibody be used to investigate STAT5B tetramer formation and chromatin binding?

The STAT5B (Ab-731) Antibody can be strategically employed to investigate STAT5B tetramer formation and chromatin interactions, particularly when used in combination with other experimental approaches. Although the antibody itself targets the Ser-731 region rather than the N-terminal domain critical for tetramerization, it can be utilized in sequential immunoprecipitation or re-immunoprecipitation studies to analyze STAT5B complexes . For examining tetramer formation, researchers should first normalize dimer-DNA binding activity of different STAT5 extracts using electrophoretic mobility shift assay (EMSA) with a single STAT5 response element (such as the beta-casein promoter element), following the detailed protocol described for titrating and adjusting DNA binding activity . Combining the Ab-731 antibody with antibodies specific for the N-terminal region in supershift assays can help verify the integrity of protein samples and confirm tetramer formation capability . For chromatin binding studies, chromatin immunoprecipitation (ChIP) using the STAT5B (Ab-731) Antibody can identify genomic binding sites, which can then be compared between wild-type STAT5B and tetramer-deficient mutants (such as STAT5b ΔN) to determine tetramer-dependent chromatin interactions . This approach is particularly valuable for studying how STAT5B tetramer formation affects chromatin structure differently from other STAT family members, potentially explaining differential cytokine responses through chromatin alterations .

What experimental approaches can distinguish between STAT5A and STAT5B functions using specific antibodies?

Distinguishing between STAT5A and STAT5B functions requires careful experimental design utilizing isoform-specific antibodies and complementary molecular techniques. The STAT5B (Ab-731) Antibody, targeting the region around serine 731, can be paired with STAT5A-specific antibodies to compare expression patterns and activation dynamics between these highly homologous proteins that nonetheless serve distinct functions . Although STAT5A and STAT5B share approximately 94% sequence identity in their protein-coding regions, they differ substantially in their C-terminal transactivation domains, allowing for the development of truly isoform-specific antibodies . Researchers can design sequential immunoprecipitation experiments where lysates are first depleted of one isoform (e.g., STAT5A) before immunoprecipitating with STAT5B (Ab-731) Antibody to isolate STAT5B-specific protein complexes and identify unique binding partners . For functional studies, combining the antibody with siRNA or CRISPR-Cas9 approaches targeting either STAT5A or STAT5B selectively can help attribute observed phenotypes to the specific isoform, as demonstrated in studies showing that STAT5A and STAT5B knockout mice exhibit distinct defects in mammary gland development and growth, respectively . Chromatin immunoprecipitation sequencing (ChIP-seq) using isoform-specific antibodies can identify unique genomic binding sites for each protein, revealing distinct transcriptional programs regulated by STAT5A versus STAT5B .

What are common technical issues when using STAT5B (Ab-731) Antibody and how can they be resolved?

When working with STAT5B (Ab-731) Antibody, researchers may encounter several technical challenges that can be systematically addressed through protocol optimization. High background in Western blots or immunohistochemistry staining is a common issue that can be resolved by increasing blocking time (2-3 hours instead of 1 hour), using alternative blocking agents (5% BSA instead of milk for phospho-sensitive applications), increasing washing frequency and duration, or optimizing antibody dilution through careful titration experiments . Weak or absent signal may occur due to insufficient antigen, which can be addressed by increasing protein loading for Western blots, optimizing cell stimulation conditions (e.g., extending EGF treatment to 45-60 minutes instead of 30 minutes), or enhancing antigen retrieval for IHC by extending heating time or trying alternative buffers like EDTA pH 9.0 instead of citrate pH 6.0 . Multiple bands in Western blots might result from protein degradation (preventable with fresher samples and additional protease inhibitors), post-translational modifications (which can be verified using lambda phosphatase treatment), or non-specific binding (reducible with more stringent washing or higher antibody dilution) . For storage-related issues, it's critical to avoid repeated freeze-thaw cycles of the antibody as mentioned in the storage recommendations, and instead prepare small single-use aliquots upon receipt and store them at -20°C or -80°C .

How should data from STAT5B phosphorylation studies be interpreted in different experimental contexts?

Interpreting STAT5B phosphorylation data requires careful consideration of the specific experimental context and activation mechanisms involved. When analyzing results from experiments using the STAT5B (Ab-731) Antibody (which detects total STAT5B) in conjunction with phospho-specific antibodies, researchers should account for the differential phosphorylation patterns induced by various stimuli . For instance, while growth hormone induces canonical Tyr-699 phosphorylation essential for STAT5B activation, EGF can induce phosphorylation at alternative sites (Tyr-725, Tyr-740, and Tyr-743) with distinct functional consequences, potentially explaining discrepancies in downstream transcriptional outcomes . Researchers should also consider the cell-type specific expressions of receptors, as EGF-induced STAT5B activation requires EGFR overexpression, which varies significantly across cell types and may explain inconsistent results when comparing different cellular models . Time-course experiments are essential for proper interpretation, as STAT5B phosphorylation typically follows rapid and transient kinetics, with peak activation often occurring within 15-30 minutes of stimulation before declining, though constitutively active mutants or pathological conditions may show sustained phosphorylation . When analyzing results from mutation studies, remember that while Tyr-699 is absolutely required for transcriptional activation, mutations at tyrosines 725, 740, and 743 revealed potential negative regulatory functions, highlighting the complex relationship between phosphorylation and transcriptional output .

What are the key considerations for quantifying STAT5B expression and activation in tissue samples?

Quantifying STAT5B expression and activation in tissue samples using the STAT5B (Ab-731) Antibody requires careful attention to multiple methodological and analytical considerations. For immunohistochemistry applications, researchers should establish a standardized scoring system based on both staining intensity (typically on a 0-3 scale) and percentage of positive cells, which can be combined to create an H-score or similar quantitative metric . Proper controls are essential, including positive control tissues known to express STAT5B (such as lymphoid tissues or mammary gland), negative control tissues with minimal STAT5B expression, and technical controls omitting primary antibody . Automated image analysis software can enhance objectivity and reproducibility when quantifying immunohistochemical staining, reducing inter-observer variability particularly important for clinical correlation studies . When examining STAT5B activation in tissues, researchers should consider the heterogeneity of the tissue, as STAT5B activation may vary between different cell types within the same sample, necessitating cell-type specific analysis through techniques like multiplexed immunofluorescence or laser capture microdissection followed by protein extraction . For studies comparing normal versus diseased tissues (such as cancer samples), matching for age, gender, and other demographic factors is critical to avoid confounding variables that might affect STAT5B expression independently of the disease process .

How can STAT5B (Ab-731) Antibody data be integrated with transcriptomic and proteomic datasets?

Integrating STAT5B (Ab-731) Antibody data with transcriptomic and proteomic datasets provides a comprehensive understanding of STAT5B's role in cellular signaling networks. Researchers can correlate protein expression levels detected by the antibody with mRNA expression data from RNA-seq or microarray experiments to identify discrepancies that might indicate post-transcriptional regulation, such as microRNA-mediated suppression or altered protein stability . For mechanistic studies, combining STAT5B protein data with ChIP-seq experiments (using the same antibody for chromatin immunoprecipitation) can map the genomic binding sites of STAT5B and correlate these with transcriptional changes, revealing direct target genes versus secondary effects . Phospho-proteomic datasets can be integrated with total STAT5B levels (detected by Ab-731) to calculate activation ratios and identify signaling networks connected to STAT5B function, particularly valuable when comparing wild-type versus mutant forms or different treatment conditions . Network analysis approaches can further integrate these multi-omic datasets to construct signaling pathway models, potentially identifying novel interactions or feedback mechanisms involving STAT5B . For clinical applications, correlating STAT5B protein levels in patient samples with transcriptome profiles may identify patient subgroups with distinct molecular features and clinical outcomes, particularly relevant in cancers where EGFR overexpression (a condition that enhances EGF-induced STAT5B activation) is common, such as advanced breast cancer .

What emerging techniques might enhance STAT5B research beyond traditional antibody applications?

Several cutting-edge technologies are poised to revolutionize STAT5B research beyond traditional antibody-based approaches, complementing studies using the STAT5B (Ab-731) Antibody. CRISPR-Cas9 gene editing enables precise modification of endogenous STAT5B, allowing researchers to introduce specific mutations (such as S731A to study the function of this phosphorylation site) or tag the protein with fluorescent or affinity markers without overexpression artifacts that might confound signaling studies . Live-cell imaging techniques combined with FRET (Förster resonance energy transfer) sensors can provide real-time visualization of STAT5B activation dynamics and nuclear translocation in response to various stimuli, offering temporal resolution not possible with fixed-cell antibody-based methods . Proximity labeling approaches like BioID or TurboID fused to STAT5B can identify transient interacting partners in living cells, potentially revealing novel regulators of STAT5B function that might be missed in traditional co-immunoprecipitation experiments . Single-cell technologies, including single-cell RNA-seq, CyTOF (cytometry by time of flight), and imaging mass cytometry can reveal cell-to-cell heterogeneity in STAT5B expression and activation within complex tissues or cell populations, providing insights into differential cellular responses to the same stimulus . Structural biology techniques, particularly cryo-electron microscopy, might elucidate the conformational changes associated with different phosphorylation states of STAT5B, including those involving serine 731, potentially explaining how these modifications affect protein-protein interactions and DNA binding .

How might STAT5B research contribute to understanding disease mechanisms and therapeutic development?

Research utilizing the STAT5B (Ab-731) Antibody and related tools has significant implications for understanding disease mechanisms and developing targeted therapeutics across multiple medical domains. In cancer biology, the discovery that EGF-induced STAT5B activation requires EGFR overexpression—a common feature in many advanced cancers including breast cancer—suggests that STAT5B signaling may contribute to tumor progression in these contexts, potentially opening avenues for targeted intervention through inhibition of this specific activation pathway . The identification of novel tyrosine phosphorylation sites (Tyr-725, Tyr-740, and Tyr-743) with potential negative regulatory functions suggests complex, context-dependent roles for STAT5B in oncogenesis, warranting further investigation using phospho-specific antibodies complementary to the Ab-731 antibody . In immunological disorders, STAT5B's critical role in lymphocyte development and function makes it a promising target for immunomodulatory therapies, with gain-of-function STAT5B mutations having been implicated in various lymphoproliferative disorders . The differential activation mechanisms by cytokines versus growth factors highlight potential pathway-specific intervention strategies that might achieve precision targeting while minimizing off-target effects . For developmental disorders, understanding STAT5B's role through knockout and mutation studies has revealed its importance in growth regulation, with STAT5B deficiency being associated with growth hormone insensitivity and severe growth failure in humans, suggesting potential applications in growth disorders .

What are the potential advantages of developing phospho-serine 731 specific antibodies for STAT5B research?

Developing phospho-serine 731 specific antibodies to complement the total STAT5B (Ab-731) Antibody would provide numerous advantages for advancing STAT5B research. Such antibodies would enable direct monitoring of this specific post-translational modification, allowing researchers to determine how serine 731 phosphorylation correlates with different activation states induced by various cytokines and growth factors, potentially revealing stimulus-specific signaling signatures . While the current Ab-731 antibody recognizes the region around serine 731 regardless of phosphorylation status, a phospho-specific antibody would distinguish between phosphorylated and non-phosphorylated forms, providing critical information about the activation dynamics and enabling quantitative assessment of the proportion of STAT5B molecules phosphorylated at this site under different conditions . The functional significance of serine 731 phosphorylation remains less characterized than tyrosine phosphorylation, and phospho-serine specific antibodies would facilitate studies investigating how this modification affects STAT5B's protein-protein interactions, DNA binding properties, nuclear-cytoplasmic shuttling, and transcriptional activity . Phospho-serine 731 antibodies would also enable examination of potential crosstalk between serine and tyrosine phosphorylation pathways, revealing whether serine phosphorylation enhances, inhibits, or is independent of the canonical tyrosine phosphorylation at sites like Tyr-699, Tyr-725, Tyr-740, and Tyr-743 . For clinical applications, such antibodies could potentially serve as biomarkers for specific activation pathways in diseases where STAT5B dysregulation is implicated, helping stratify patients and predict response to targeted therapies .